# BeOne Medicines: Phase 1 study in Diffuse Large B-Cell Lymphoma, B-cell Malignancies (70 participants)

**Score:** 50/100

| Field | Value |
|---|---|
| Sponsor | BeOne Medicines |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0920 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies |
| NCT ID | NCT07887646 |
| Phase | Phase 1 |
| Status | not yet recruiting |
| Conditions | Diffuse Large B-Cell Lymphoma; B-cell Malignancies |
| Intervention types | drug |
| Target enrollment | 70 |
| Posted | 2026-10-21 |
| Planned start | 2026-12-11 |
| Event | Newly registered study |
| Event date | 2026-10-21 |

## Why this score
- Industry sponsor (buys outsourced services).
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07887646). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.